Literature DB >> 8027054

Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man.

P J Bosma1, J Seppen, B Goldhoorn, C Bakker, R P Oude Elferink, J R Chowdhury, N R Chowdhury, P L Jansen.   

Abstract

Crigler-Najjar syndrome type I (CN-I) is caused by an inherited absence of UDP-glucuronosyltransferase activity toward bilirubin (B-UGT), resulting in severe non-hemolytic unconjugated hyperbilirubinemia. Based on the expression of cDNAs in COS cells, two UGT isoforms in human liver, B-UGT1 and B-UGT2, have been reported to catalyze bilirubin glucuronidation. These isoforms, which are derived from a single gene, ugt1, have identical carboxyl-terminal domains that are encoded by four consecutive exons shared by both isoforms. A critical lesion in any of these common exons should inactivate both B-UGT isoforms, giving rise to CN-I. The amino-terminal domains of the B-UGT isoforms are unique, each being encoded by a different 5' exon. If both B-UGT isoforms contribute significantly to bilirubin glucuronidation, a mutation in one of these unique 5' exons should affect a single isoform, while the other isoforms should provide residual B-UGT activity. However, in two patients with CN-I, we found a mutation only in the unique exon of B-UGT1, the other exons being normal. To clarify this apparent paradox, we expressed the cDNA for each B-UGT isoform in COS cells and determined the specific B-UGT activity. These studies show that only B-UGT1 has quantitatively significant catalytic activity. Furthermore, we show that the mutation in B-UGT1 observed in each of the two CN-I patients inactivates B-UGT1. Together, the results indicate that B-UGT1 is the only physiologically relevant isoform in bilirubin glucuronidation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8027054

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  81 in total

Review 1.  Glucuronidation in humans. Pharmacogenetic and developmental aspects.

Authors:  S N de Wildt; G L Kearns; J S Leeder; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1999-06       Impact factor: 6.447

2.  Induction of UDP-glucuronosyltransferase UGT1A1 by the flavonoid chrysin in Caco-2 cells--potential role in carcinogen bioinactivation.

Authors:  A Galijatovic; Y Otake; U K Walle; T Walle
Journal:  Pharm Res       Date:  2001-03       Impact factor: 4.200

3.  Disruption of the c/ebp alpha gene in adult mouse liver.

Authors:  Y H Lee; B Sauer; P F Johnson; F J Gonzalez
Journal:  Mol Cell Biol       Date:  1997-10       Impact factor: 4.272

Review 4.  Regulatable fatty acid transport mechanisms are central to the pathophysiology of obesity, fatty liver, and metabolic syndrome.

Authors:  Paul D Berk
Journal:  Hepatology       Date:  2008-11       Impact factor: 17.425

5.  Regulation of UDP-glucuronosyltransferase 1A1 expression and activity by microRNA 491-3p.

Authors:  Douglas F Dluzen; Dongxiao Sun; Anna C Salzberg; Nate Jones; Ryan T Bushey; Gavin P Robertson; Philip Lazarus
Journal:  J Pharmacol Exp Ther       Date:  2014-01-07       Impact factor: 4.030

6.  Bilirubin uridine diphosphate-glucuronosyltransferase variation is a genetic basis of breast milk jaundice.

Authors:  Yoshihiro Maruo; Yoriko Morioka; Hiroshi Fujito; Sayuri Nakahara; Takahide Yanagi; Katsuyuki Matsui; Asami Mori; Hiroshi Sato; Robert H Tukey; Yoshihiro Takeuchi
Journal:  J Pediatr       Date:  2014-03-17       Impact factor: 4.406

7.  Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species.

Authors:  Chen-Chun Zhong; Feng Chen; Jun-Ling Yang; Wei-Wei Jia; Li Li; Chen Cheng; Fei-Fei Du; Su-Ping Zhang; Cheng-Ying Xie; Na-Ting Zhang; Olajide E Olaleye; Feng-Qing Wang; Fang Xu; Li-Guang Lou; Dong-Ying Chen; Wei Niu; Chuan Li
Journal:  Acta Pharmacol Sin       Date:  2018-04-05       Impact factor: 6.150

8.  The effect of UGT1A1 promoter polymorphism in the development of hyperbilirubinemia and cholelithiasis in hemoglobinopathy patients.

Authors:  Suad AlFadhli; Hassan Al-Jafer; Mays Hadi; Mashael Al-Mutairi; Rasheeba Nizam
Journal:  PLoS One       Date:  2013-10-30       Impact factor: 3.240

Review 9.  Excretion of biliary compounds during intrauterine life.

Authors:  Rocio I R Macias; Jose J G Marin; Maria A Serrano
Journal:  World J Gastroenterol       Date:  2009-02-21       Impact factor: 5.742

Review 10.  Liver cell transplantation for Crigler-Najjar syndrome type I: update and perspectives.

Authors:  Philippe-A Lysy; Mustapha Najimi; Xavier Stephenne; Annick Bourgois; Francoise Smets; Etienne-M Sokal
Journal:  World J Gastroenterol       Date:  2008-06-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.